BrainStorm Cell Therapeutics Announces Adult Stem Cell Breakthrough For Neurodegenerative Diseases
BrainStorm Cell Therapeutics, today announced a breakthrough in the development of adult stem cell therapeutics for neurodegenerative diseases. The company’s scientific collaborators at Tel Aviv University, have successfully used adult stem cells to produce glial derived neurotrophic factor (GDNF).
BD(TM) PuraMatrix(TM) Synthetic Hydrogels Featured in BD Biosciences Inaugural Web Seminar Series
The seminar will focus on the use of PuraMatrix™ as a novel synthetic extracellular matrix analogue, enabling improvements across applications such as defined cell-based assays for drug discovery and stem cell research, 3-D cell culture, cellular microenvironment studies, bioproduction and tissue engineering.
Biomira Exercises Option to Acquire Stake in Australia’s Prima BioMed Ltd.
Cancer vaccine developer Biomira Inc. said Tuesday it has exercised an option to acquire a stake in Prima BioMed Ltd., an Australian biotech company, for an undisclosed price.
Cerus Corporation Appoints Dr. Joseph Eiden Vice President, Clinical Research and Medical Affairs
Cerus Corporation today announced that Dr. Joseph Eiden has joined the company as vice president, clinical research and medical affairs. Dr. Eiden will oversee the company’s clinical development efforts.
Alethia BioTherapeutics, Inc., is Issued a European Patent For Its Target Discovery Technology
Alethia BioTherapeutics, Inc., a biotechnology with innovative approaches for the treatment of cancer and related diseases, is pleased to announce the issuance of European Patent No. EP0914470, “Subtractive Amplification.”
Cytori Therapeutics Reports Adipose-Derived Stem Cells Home to, Engraft and Repair Injured Heart Muscle in Preclinical Model of Heart Attack-Like Injury
“Our results expand upon our earlier preliminary findings that ADCs may repair or minimize damage to an injured heart through multiple mechanisms, including differentiation into heart muscle and through the recruitment of oxygen to the damaged area through the induction of blood vessel growth,” said Marc H. Hedrick, M.D., President for Cytori Therapeutics.
Dendreon’s Second Randomized Phase 3 D9902A Trial Shows Provenge Extends Survival in Patients with Advanced Prostate Cancer
Dendreon Corporation today announced that the analysis of the final three-year survival data of its second Phase 3 study (D9902A) of Provenge(R), the Company’s investigational active immunotherapy for the treatment of prostate cancer, showed a survival benefit in men with advanced prostate cancer who were treated with Provenge.
Genzyme Launches Minimal Residual Disease Test for Common Leukemia
Genzyme Corporation announced today that it has launched a new test to detect very low levels of disease, also known as minimal residual disease (MRD), in patients with B-cell chronic lymphocytic leukemia (B-CLL).
Human BioSystems Successfully Transplants Kidneys Stored at Suspended Animation Temperatures
Human Biosystems announces today that it was successful in transplanting animal kidneys preserved in the Company’s proprietary “HBS Preservation Solution” after being stored in liquid Nitrogen at -196 degrees Centigrade.
Introgen’s INGN 241 Cancer Therapy Triggers Immune System to Kill Cancer Cells
Researchers at Introgen Therapeutics, Inc. and their collaborators at The University of Texas M. D. Anderson Cancer Center have published new findings on the role of IL-24 in regulating the immune system in the current online issue of the Journal of Leukocyte Biology.
Invitrogen Opens Australian cGMP Manufacturing Facility; New Operation Increases Worldwide Capacity in Serum Development Invitrogen Corporation, the leading provider of essential life science technologies for disease research and drug discovery, today announced the opening of a new cGMP bioproduction facility focused on development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.
Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies
Under the terms of the agreement, Xencor’s XmAb(TM) engineered antibody Fc domains will be used to create antibody drug candidates that Centocor will evaluate against an oncology target.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents